Key terms
About AZN
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest AZN news
Yesterday
6:25am ET
AstraZeneca, Sanofi announce Beyfortus approved in Japan
Yesterday
6:24am ET
AstraZeneca’s Truqap with Faslodex approved by Japanese MHLW
Mar 26
5:07am ET
QQQ ETF Update, 3/26/2024
Mar 25
7:57am ET
AstraZeneca’s Ultomiris Revolutionizes NMOSD Treatment
Mar 25
7:10am ET
FDA approves AstraZeneca’s Ultomiris for rare nerve disease NMOSD
Mar 25
6:17am ET
AstraZeneca reports Ultomiris approved in U.S. for adults with NMOSD
Mar 22
5:58am ET
QQQ ETF Update, 3/22/2024
Mar 21
11:36am ET
AstraZeneca put volume heavy and directionally bearish
Mar 21
10:16am ET
AstraZeneca reports follow up results from FLAURA2 Phase 3 trial
Mar 21
2:51am ET
Analysts Offer Insights on Healthcare Companies: Structure Therapeutics, Inc. Sponsored ADR (GPCR), AstraZeneca (AZN) and Biohaven Ltd. (BHVN)
Mar 20
9:57am ET
Wells Fargo downgraded, Best Buy upgraded: Wall Street’s top analyst calls
Mar 20
8:21am ET
Fusion Pharmaceuticals downgraded to Neutral from Buy at B. Riley
Mar 20
8:19am ET
Fusion Pharmaceuticals downgraded to Market Perform from Strong Buy at Raymond James
Mar 20
6:54am ET
Fusion downgraded to Sector Perform from Outperform at RBC Capital
Mar 20
6:49am ET
QQQ ETF Update, 3/20/2024
Mar 20
6:30am ET
Wall Street Analysts Are Bullish on Top Healthcare Picks
Mar 19
10:17pm ET
Puma Biotechnology says court denied AstraZeneca’s motion for invalidity
Mar 19
1:32pm ET
This radiopharma name seen as ‘poised for takeout’ following Fusion deal
Mar 19
12:55pm ET
Actinium Pharmaceuticals price target raised to $30 from $20 at Maxim
Mar 19
11:23am ET
Actinium positioned for takeout after Fusion deal, says H.C. Wainwright
Mar 19
10:06am ET
Fusion Pharmaceuticals downgraded to Hold from Buy at Jefferies
Mar 19
9:53am ET
Snowflake, MongoDB downgraded to Sell: Wall Street’s top analyst calls
Mar 19
6:58am ET
AstraZeneca Bolsters Cancer Care with Fusion Buyout
Mar 19
6:08am ET
Fusion Pharmaceuticals downgraded to Market Perform from Outperform at Leerink
Mar 19
5:20am ET
Fusion Pharmaceuticals to be acquired by AstraZeneca in $2.4B transaction
Mar 19
2:21am ET
Analysts Offer Insights on Healthcare Companies: AstraZeneca (AZN), Intuitive Surgical (ISRG) and IN8bio (INAB)
Mar 18
8:17am ET
Checkpoint Therapeutics appoints Sharma to board of directors
Mar 18
8:14am ET
AstraZeneca announces analysis from its DUO-E Phase III trial
Mar 18
7:19am ET
AstraZeneca to expand savings programs for inhaled U.S. respiratory portfolio
Mar 18
2:01am ET
QQQ ETF Update, 3/18/2024
Mar 15
12:03pm ET
JPMorgan biotech/pharma analysts hold an analyst/industry conference call
Mar 13
11:00am ET
European Stocks: Unnoticed Records, Overlooked Opportunities
No recent press releases are available for AZN
AZN Financials
Key terms
Ad Feedback
AZN Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
AZN Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range